Clinical trials: Stroke; Sequelae
Stroke, Stroke, Ischemic
MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits
This is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 high-dose twice a day, MLC1501…
- Conditions
- Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae
- Trial name
- MAESTOSO (NCT05289947)
- Testing
- MLC1501
- Where
- 11 sites in Philippines, Singapore
- Volunteers
- 303 people
- Sponsor
- Moleac Pte Ltd.
Spasticity as Sequela of Stroke
Spasticity and Treatment Satisfaction Among Stroke Survivors
To investigate, through ethnography, changes in symptom burden and disability and their effects/interference on patient functioning, ability to perform activities of daily living (ADL) and quality of life (QoL) throughout the…
- Trial name
- REBOT (NCT03995524)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Ipsen
Spasticity as Sequela of Stroke
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
This study will monitor patients during the first year following their stroke. Stroke is a very serious condition where there is a sudden interruption of blood flow in the brain.
- Trial name
- EPITOME (NCT06055725)
- Where
- 55 sites in United States, France and 5 more
- Volunteers
- 1,057 people
- Sponsor
- Ipsen
Stroke, Hemiparesis
Fully Remote Use of IpsiHand Device in Hemiparetic Stroke
BCI-REHAB was a randomized clinical trial comparing an at-home brain-computer interface therapy system versus an at-home exercise program for upper-extremity rehabilitation in the chronic phases of stroke.
- Conditions
- Stroke, Hemiparesis, Spasticity as Sequela of Stroke, Brain Computer Interface
- Trial name
- NCT05965713
- Testing
- Neurolutions IpsiHand Upper Extremity Rehabilitation System, Home Exercise rehabilitation regimen Program (HEP)
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Neurolutions, Inc.
Stroke, Stroke, Ischemic
MLC1501 Study Assessing Efficacy in STROke Recovery
This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a…
- Conditions
- Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae
- Trial name
- MAEStro (NCT05046106)
- Testing
- MLC1501
- Volunteers
- 540 people
- Sponsor
- Moleac Pte Ltd.
Stroke Sequelae, Stroke
Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy Volunteers
An Open-label, One-sequence, Three-period, Multiple-dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability between NDC-002A/NDC-002B and NDC-002C in Healthy Volunteers
- Trial name
- NCT06090474
- Testing
- NDC-002
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Dr. Noah Biotech Inc.
Stroke Sequelae, Cognitive Impairment
Remote Bimanual Virtual Rehabilitation Post CVD
The aim of the study is to develop the BrightBrainer G (grasp), a game-based upper-extremity motor and cognitive rehabilitation system using custom virtual reality simulations.
- Conditions
- Stroke Sequelae, Cognitive Impairment, Depression
- Trial name
- NCT04713384
- Testing
- Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Grigore Burdea
Ischemic Stroke in the Sequelae Stage
ALT001 in Patients With Ischemic Stroke in the Sequelae Stage
This is a phase II, randomized, double-blind, placebo-controlled, multicentre clinical study to evaluate the efficacy and safety of ALT001 in patients with ischemic stroke in the sequelae stage (≥180 days and ≤5 years after the…
- Trial name
- NCT07841496
- Testing
- ALT001
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.
Stroke Sequelae
Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke
Following stroke, a recovery process is promptly initiated, which leads to a partial rehabilitation. However, a number of disabling residual symptoms may persist for years and include mental fatigue, depression, cognitive…
- Trial name
- OSU6162DB003 (NCT04127669)
- Testing
- OSU 6162
- Where
- Sweden
- Volunteers
- 101 people
- Sponsor
- Arvid Carlsson Research AB
Endovascular Thrombectomy, Ischemic Cerebrovascular Accident
A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke
The MaTRISS 2 study is a phase 2 randomized, double-blinded and placebo-controlled trial aimed at recruiting 60 subjects (30 placebo and 30 active) from 15 stroke centers in France.
- Trial name
- MATRISS-II (NCT06700824)
- Testing
- OTR4132
- Where
- 15 sites in France
- Volunteers
- 60 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement